Complement factor B targeting small interfering RNA - Argo Biopharma
Alternative Names: CFB siRNALatest Information Update: 04 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Small interfering RNA
- Mechanism of Action Complement factor B expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical IgA nephropathy; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 21 Feb 2024 Complement factor B targeting small interfering RNA - Argo Biopharma is available for licensing as of 21 Feb 2024. https://www.argobiopharma.com/partnering/index.html (Argo Biopharma pipeline, February 2024)
- 21 Feb 2024 Preclinical trials in IgA nephropathy in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)
- 21 Feb 2024 Preclinical trials in Myasthenia gravis in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)